- CMBI analyst Jill Wu reaffirmed a Buy rating on Sichuan Kelun-Biotech Biopharmaceutical and raised its target price from 507.11 HKD to 642.29 HKD.
- The rating is driven by strong operational and clinical momentum, featuring better-than-expected sac-TMT commercialization and profit turnaround fueled by NRDL adoption.
- Increased confidence in global and domestic Phase III clinical trials and Merck-led combination projects supports the higher valuation and blockbuster potential.
